Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Cantor Fitzgerald
QuintilesIMS
US Department of Justice
Farmers Insurance
Chubb
McKinsey
Teva
Novartis
Federal Trade Commission

Generated: August 16, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 8,722,037 protect, and when does it expire?


Patent ► Subscribe protects NEXPLANON and is included in one NDA.

This patent has thirty-two patent family members in thirty-one countries.

Summary for Patent: ► Subscribe

Title:X-ray visible drug delivery device
Abstract: The subject invention provides an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy.
Inventor(s): Veenstra; Harm (Oss, NL), De Graaff; Wouter (Oss, NL)
Assignee: Meck Sharp & Dohme B.V. (BN Harleem, NL)
Application Number:10/592,725
Patent Claim Types:
see list of patent claims
Compound; Delivery; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Organon Usa Inc
NEXPLANON
etonogestrel
IMPLANT;IMPLANTATION021529-002May 31, 2011RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04101151Mar 19, 2004
PCT Information
PCT FiledMarch 14, 2005PCT Application Number:PCT/EP2005/051150
PCT Publication Date:September 29, 2005PCT Publication Number: WO2005/089814

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1729819► Subscribe
Peru00222006► Subscribe
New Zealand549877► Subscribe
Norway20064716► Subscribe
Malaysia142649► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
US Department of Justice
Deloitte
Julphar
Dow
Baxter
McKesson
Mallinckrodt
Cantor Fitzgerald
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot